Cargando…

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey

BACKGROUND: Recent advances occurred in the field of Alzheimer’s disease (AD) biomarkers and the introduction of a research framework grounded on a biomarker-based definition of AD might have fostered an increased clinical use of AD biomarkers. For this reason, an up-to-date depiction of the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caprioglio, Camilla, Garibotto, Valentina, Jessen, Frank, Frölich, Lutz, Allali, Gilles, Assal, Frédéric, Frisoni, Giovanni B., Altomare, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535580/ https://www.ncbi.nlm.nih.gov/pubmed/35912743 http://dx.doi.org/10.3233/JAD-220333

Ejemplares similares

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment
por: Frederiksen, Kristian Steen, et al.
Publicado: (2020)

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact
por: Collij, Lyduine E., et al.
Publicado: (2023)

Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)
por: Chincarini, A., et al.
Publicado: (2019)

The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging
por: Bommarito, Giulia, et al.
Publicado: (2022)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
por: Altomare, Daniele, et al.
Publicado: (2023)

Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study
por: Pagani, M., et al.
Publicado: (2014)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns
por: Achard, Vérane, et al.
Publicado: (2021)

Specific EEG Changes Associated with Atrophy of Hippocampus in Subjects with Mild Cognitive Impairment and Alzheimer's Disease
por: Moretti, D. V., et al.
Publicado: (2012)

Lifelong bilingualism and mechanisms of neuroprotection in Alzheimer dementia
por: Sala, Arianna, et al.
Publicado: (2021)

Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer’s disease: how and what to tell. A kickstart to an ethical discussion
por: Porteri, Corinna, et al.
Publicado: (2014)

The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
por: Belleville, Sylvie, et al.
Publicado: (2019)

The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort
por: Ribaldi, Federica, et al.
Publicado: (2023)

In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
por: Tournier, Benjamin B., et al.
Publicado: (2020)

Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment
por: Lacour, A, et al.
Publicado: (2017)

Exploring Genetic Associations of Alzheimer’s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes
por: Espinosa, Ana, et al.
Publicado: (2018)

The Fornix in Mild Cognitive Impairment and Alzheimer’s Disease
por: Nowrangi, Milap A., et al.
Publicado: (2015)

Judgment in Mild Cognitive Impairment and Alzheimer's disease
por: Capucho, Patrícia Helena Figueirêdo Vale, et al.
Publicado: (2011)

Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank
por: Vitek, Michael P., et al.
Publicado: (2021)

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia
por: Frölich, Lutz, et al.
Publicado: (2017)

Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit
por: Frölich, Lutz, et al.
Publicado: (2021)

Severe agitation in severe early-onset Alzheimer’s disease resolves with ECT
por: Aksay, Suna Su, et al.
Publicado: (2014)

Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study
por: Petersen, Melissa E., et al.
Publicado: (2020)

Writing Impairments in Japanese Patients with Mild Cognitive Impairment and with Mild Alzheimer's Disease
por: Hayashi, Atsuko, et al.
Publicado: (2015)

Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer’s disease
por: Jiang, Xiong, et al.
Publicado: (2021)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases
por: Sala, Arianna, et al.
Publicado: (2021)

The Early Diagnosis of Alzheimer’s Disease: A Patient-Centred Conversation with the Care Team
por: Nasreddine, Ziad, et al.
Publicado: (2022)

Automatic morphometry in Alzheimer's disease and mild cognitive impairment()()
por: Heckemann, Rolf A., et al.
Publicado: (2011)

Brain imaging of mild cognitive impairment and Alzheimer's disease
por: Yin, Changhao, et al.
Publicado: (2013)

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease
por: Chalermpalanupap, Termpanit, et al.
Publicado: (2013)

Anosognosia and Anosodiaphoria in Mild Cognitive Impairment and Alzheimer's Disease
por: Lindau, Maria, et al.
Publicado: (2014)

Prospective memory in Alzheimer’s disease and Mild Cognitive Impairment
por: Spíndola, Lívia, et al.
Publicado: (2011)

Peripheral reaching in Alzheimer's disease and mild cognitive impairment
por: Mitchell, Alexandra G., et al.
Publicado: (2022)

Olfactory memory in mild cognitive impairment and Alzheimer’s disease
por: Audronyte, Egle, et al.
Publicado: (2023)

Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network
por: Benson, Gloria S., et al.
Publicado: (2022)

Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimer’s Disease
por: Cova, Ilaria, et al.
Publicado: (2016)

A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
por: Nordberg, Agneta, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5glgeo50c285d4d6tupkufubqp